Article
Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
The Journal of clinical endocrinology and metabolism - 1 Aug 2003
Guerin Maryse, Le Goff Wilfried, Frisdal Eric, Schneider Séverine, Milosavljevic Dragana, Bruckert Eric, Chapman M John
Abstract excerpt
The effects of ciprofibrate (100 mg/d) on apolipoprotein (apo)B- and apoAI-containing lipoprotein subclasses, cholesteryl ester (CE) transfer protein activity, and plasma high-density lipoprotein (HDL)-mediated cellular cholesterol efflux were evaluated in 10 patients displaying type IIB hyperlipidemia. Plasma concentrations of large very low-density lipoprotein (VLDL)-1 (Sf 60-400) and of small VLDL-2 (Sf 20-60)...
Topics
- Adult
- Animals
- Apolipoprotein A-I
- Apolipoproteins B
- Arteriosclerosis
- Cholesterol
- Cholesterol Esters
- Clofibric Acid
- Cyclic AMP
- Fibric Acids
- Humans
- Hyperlipoproteinemia Type II
- Hypolipidemic Agents